Aktieanalys

Orexo: Nasal adrenaline rescue medication OX640 enters clinical development - Redeye

{newsItem.title}

Redeye Publicerad: 05 Jul 2022 19:07

Redeye is encouraged to learn that Orexo has initiated the clinical development of Orexo’s OX640 product, a nasal adrenaline formulation based on Orexo’s novel drug delivery platform amorphOX®.

Länk till analysen i sin helhet: https://www.redeye.se/research/848088/orexo-nasal-adrenaline-rescue-medication-ox640-enters-clinical-development?utm_source=finwire&utm_medium=RSS

Nyheter om Orexo

Läses av andra just nu

Om aktien Orexo

Senaste nytt